Total
0
Shares
EMVision (ASX:EMV) - Managing Director & CEO, Ron Weinberger (right) and Head of Technology Development, Dr Konstanty Bialkowski (left)
Managing Director & CEO, Ron Weinberger (right) and Head of Technology Development, Dr Konstanty Bialkowski (left)
Source: Stockhead
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical imaging specialist EMVision (EMV) has appointed CEO Dr Ron Weinberger to its Board and made him Managing Director
  • Ron has been CEO of EMVision since 2018 and has helped the company hit some important milestones for its portable brain scan tech
  • Today, Executive Chairman John Keep is transitioning his role to Non-Executive Chairman
  • This gives Ron, as both CEO and Managing Director, more control over the company’s day-to-day operations
  • EMVision listed on the ASX in December 2018 with a 25-cent initial public offering
  • Today, shares are trading grey and worth 89 cents each

Medical imaging specialist EMVision (EMV) has appointed CEO Dr Ron Weinberger to its Board and given him the added role of Managing Director.

Ron has been the EMVision CEO since 2018. It seems the company’s management team has been pleased with how he’s run the company since then.

EMVision listed on the ASX in December 2018 with a 25-cent initial public offering (IPO). Today, shares are trading for 89 cents each.

The company’s share price has completely recovered from the mid-March COVID-19 sell-off. Moreover, promising results from recent clinical trials and a solid balance sheet suggest the company is well-positioned for growth as it stands.

EMVision Chairman John Keep said Ron’s “deep expertise” in innovation and product development has so far been invaluable to the company.

“Ron’s appointment follows the positive outcomes achieved thus far in our pilot clinical trial,” John said.

“We look forward to Ron’s ongoing leadership in this incredibly exciting next stage of EMVision’s growth and strategic development,” he said.

In fact, John will be transitioning his role of Executive Chairman to Non-Executive Chairman. This gives Ron more control of day-to-day operations while leaving John in charge of the Board.

Ron said he was honoured to be made a part of the EMVision Board and given more of the reins.

“We have reached some exciting milestones and there is substantial opportunity ahead,” Ron said.

At the heart of the company’s success, he said, is EMVision’s collaborative work with the University of Queensland, Princess Alexandra Hospital, and Tiller Design, along with other clinical advisors.

The Board seems to be placing some solid bet’s on Ron’s future performance, too: with his appointment comes the issue of one million options over ordinary shares, exercisable at $1.25 each within three years.

Before joining the EMVision team, Ron was CEO of fellow ASX-listed Nanosonics (NAN) — a $2 billion-market-cap company specialising in ultrasound medical devices.

EMVision shares are trading grey in early-afternoon trade, currently worth 89 cents each.

EMV by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.